| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Neonatology and Paediatric Intensive Care Medicine, Dept of General Paediatrics, and 2 Dept of Pathology, Heinrich-Heine-University, Düsseldorf, Germany, 3 Dept of Pathology, Glasgow Royal Infirmary, and 4 Dept of Physiology and Pharmacology, University of Strathclyde, Glasgow, UK.
CORRESPONDENCE: T. Hoehn, Neonatology and Paediatric Intensive Care Medicine, Dept of General Paediatrics, Heinrich-Heine-University, Moorenstr. 5, D-40225 Düsseldorf, Germany. Fax: 49 2118119786. E-mail: thomas.hoehn{at}uni-duesseldorf.de
Keywords: Endothelial cells, endothelial nitric oxide synthase, inducible nitric oxide synthase, inhaled nitric oxide, newborn, nitrotyrosine
Received: July 15, 2005
Accepted November 5, 2005
 |
ABSTRACT |
|---|
 TOP ABSTRACT MATERIAL AND METHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
This case study aims to determine the cellular source and topographical distribution of the nitric oxide synthases in CPL. It studies the post mortem tissue of a term newborn with the clinical course and histological findings of CPL and three controls without pulmonary pathology.
It was found that endothelial cells of pulmonary arteries and lymphatic structures stained significantly more for endothelial nitric oxide synthase protein in the CPL patient compared to the controls.
The authors conclude that synthesis of endothelial nitric oxide synthase is upregulated in vascular and lymphatic endothelial cells in congenital pulmonary lymphangiectasis.
Congenital pulmonary lymphangiectasis (CPL) is a rare disease of the term newborn, which was originally described by R. Virchow almost 150 yrs ago 1, 2. Congenital dilatation of the pulmonary lymphatic vessels is the key feature of this disease and has been classified according to its presence in other organs and the existence of associated malformations 3. In the majority of cases, cyanosis is present shortly after birth, though diagnosis can be delayed for several weeks in cases of unilobar presentation 4. Mortality is higher if both lungs are affected 5, and early foetal signs can be those of non-immune hydrops foetalis 6. Congenital anomalies (cardiac and renal) have been reported in >50% of cases of CPL 5, and in one case, CPL was caused by thoracic duct agenesis 7. Although primarily a disease of the term newborn, CPL can present in the pre-term infant and spontaneous resolution of the condition can occur 8.
This study describes the findings of immunohistochemical staining for the nitric oxide synthases (NOS), endothelial NOS (eNOS), inducible NOS (iNOS) and neuronal NOS (nNOS) in a term newborn with CPL.
|
MATERIAL AND METHODS |
|---|
|
TOPABSTRACTMATERIAL AND METHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
Controls
Control subjects were chosen from infants who had died from sudden infant death syndrome and had an autopsy performed at the Dept of Paidopathology and Placentology of Humboldt Univesity (Charité Virchow Hospital, Berlin, Germany). None of the infants was resuscitated by medical personnel, there were no therapeutic interventions (e.g. mechanical ventilation) nor was there evidence of pulmonary infection in any of the infants.
Control 1
Infant of a 15-yr-old primigravida, with maternal cigarette smoking. The term infant had a birth weight of 3,000 g, an APGAR of 9/10 and an arterial cord pH of 7.29. Diarrhoea was noted 10 days prior to death. The infant died on day 73 of life.
Control 2
Infant of a 22-yr-old primigravida, with a history of smoking. The term infant had a birth weight of 2,740 g, an APGAR of 8/10 and an arterial cord pH of 7.24. The infant died on day 86 of life.
Control 3
Infant from the second pregnancy of a 24-yr-old mother, with a history of smoking. Delivery was at 39 weeks of gestation and the infant had a birth weight of 2,610 g, meconium-stained amniotic fluids, an APGAR of 9/9 and an arterial cord pH of 7.29. Local fungal infection of mouth and skin occurred at 8 weeks of age. The infant died on day 137 of life.
Methodology for immunocytochemistry
Lung tissue was supplied as paraffin-embedded tissue blocks. Sections (4 µm) were cut from the blocks, rehydrated and then antigen was retrieved by microwave pressure cooking or trypsin incubation. The sections were treated to block nonspecific binding of primary and secondary antibodies and nonspecific reaction with chromogens as described previously 9. The sections were then incubated with the specific antibody for 60 min at room temperature (eNOS: catalogue No. N30020
[GenBank]
, BD Transduction, Lexington, KY, USA; 1:200; pre-treatment was pressure cooking. iNOS: Cat. No. N32020
[GenBank]
, BD Transduction; 1:500; pre-treatment was pressure cooking. nNOS: Cat. No. 610308, BD Biosciences, Oxford, UK; 1:400; pre-treatment was pressure cooking. Nitrotyrosine: Cat. No. 06-284, Upstate Biotechnology, Lake Placid, NY, USA; 1:200; pre-treatment was trypsin incubation). Nitrotyrosine staining was included in order to verify whether or not sufficient NO was formed to induce the formation of peroxynitrite, as indicated by tyrosine nitration. Bound antibody was detected using goat anti-mouse immunoglobulin G conjugated with horseradish peroxidase using a streptavidin-biotin link and visualised with diaminobenzidine. In negative controls, the primary antibody was replaced with pre-immune serum. Sections were counterstained using haematoxylin and viewed by light microscopy.
Vessels with an internal diameter <250 µm were regarded as small pulmonary arteries, whereas those >250 µm were regarded as large pulmonary arteries.
|
RESULTS |
|---|
|
TOPABSTRACTMATERIAL AND METHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
), the latter usually being negative for eNOS. There was also mild positive staining of the endothelial lining of some of the ectatic lymphatic channels.
|
).
Inducible nitric oxide synthase
Mild-to-moderate endothelial positivity was present in medium and small pulmonary artery branches, which also showed some smooth muscle staining (fig. 2a). Some of the ectatic lymphatic channels showed mild endothelial positivity, although in some areas the endothelial lining had been lost. Moderate positivity was also present in bronchial epithelial cells and mild positivity was seen in alveolar lining cells.
|
).
Neuronal nitric oxide synthase
Lymphatic and pulmonary artery structures had no convincing positive staining in either the patient or the controls (fig. 3a and b). nNOS was detected in the airway epithelium in both groups.
|
In controls, the media of pulmonary arteries stained lightly for nitrotyrosine.
Staining details have been summarised in table 1.
|
|
DISCUSSION |
|---|
|
TOPABSTRACTMATERIAL AND METHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
Although not uniformly a fatal disease 10–12, neonatal presentation of bilateral CPL is associated with severe compromise of pulmonary gas exchange as well as high mortality. Neither clinical presentation nor macroscopic aspect during surgery allow definite differentiation between CPL and congenital lobar emphysema 13 or between CPL and pulmonary lymphangioma 14. Extrapulmonary manifestation of lymphangiectasis is not necessarily associated with better pulmonary gas exchange 15. Recently, the present authors have shown upregulation of eNOS in patients with rapid progressive pulmonary hypertension of the newborn (RPPHN) 9. Hypoxia could be expected to act as a trigger for eNOS upregulation both in RPPHN as well as in CPL. The main difference between RPPHN and CPL regarding eNOS upregulation is the time axis: whereas infants with RPPHN were several weeks of age at the time of biopsy or autopsy, the infant with CPL was only 9 h of age. One possible explanation for the early upregulation of eNOS in the present case could be the degree of hypoxia. Arterial partial pressures of oxygen in the present patient were 1.2–3.2 kPa and therefore lower than normal foetal intra-uterine oxygen levels (which range 3.6–4.7 kPa) 16.
The second interesting finding consisted of eNOS expression in lymphatic endothelial cells, which are so prominent and pathogenic in CPL. Earlier in vitro investigations have established a model for the study of microlymphatics 17 and have provided evidence of NO production by lymphatic endothelial cells 18. Depending on the type of stimulus (Ca ionophore or lipopolysaccharide), NO production was mediated by eNOS or by iNOS upregulation 19. In vivo studies in C57BL/6 mice have shown that eNOS affects lymphatic fluid flow without affecting the diameter of the initial lymphatics 20. Lymphatic flow appears to be regulated by the collecting lymphatics and the degree of outflow resistance, which was regulated by eNOS.
Upregulation of iNOS does not appear to be a feature of CPL. In a rat model of pulmonary hypertension, initial upregulation of iNOS subsided after several days, leaving upregulation of eNOS the predominant finding 21.
Although there is reason to believe that treatment with NO does not influence eNOS expression, this possibility cannot be excluded. At least in a rat model of pulmonary hypertension, the addition of NO to the study gas did not modify pulmonary eNOS expression 22.
At this stage it can only be speculated what effect endothelial nitric oxide synthase upregulation in vascular endothelial cells and in lymphatic endothelial cells has on the resulting degree of hypoxia. Nitric oxide formation would result in vasodilation with reduced vascular resistance, increased pulmonary blood flow and improved oxygenation in the case of vascular endothelial cells. Vasodilation in pulmonary lymphatics could mean less outflow resistance, improved pulmonary clearance of lymphatic fluids and, again, improved oxygenation. In the present case at least, not even the addition of exogenous nitric oxide by means of inhalation was sufficient to reverse profound hypoxia nor to prevent severe acidosis and, ultimately, death.
|
ACKNOWLEDGEMENTS |
|---|
|
TOPABSTRACTMATERIAL AND METHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTMATERIAL AND METHODSRESULTSDISCUSSIONACKNOWLEDGEMENTSREFERENCES |
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
